CytomX Therapeutics Inc. (NASDAQ:CTMX) saw a downside of -3.09% to $2.66 after subtracting -$0.09 on Wednesday. The 5-day average trading volume is 1,981,486 shares of the company’s common stock. It has gained $2.80 in the past week and touched a new high 2 times within the past 5 days. An average of 5,541,236 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,704,769.
CTMX’s 1-month performance is 82.12% or $1.10 on its low of $1.43 reached on 12/27/22. The company’s shares have touched a 52-week low of $1.17 and high of $4.73, with the stock’s rally to the 52-week high happening on 01/09/23. YTD, CTMX has achieved 71.87% or $1.04 and has reached a new high 5 times. However, the current price is down -43.66% from the 52-week high price.
CTMX stock investors last saw insider trading activity on Jul 20.Peterson Amy C. (EVP, Chief Development Officer) most recently sold 7,463 shares at $1.42 per share on Jul 20. This transaction cost the insider $10,612. Chief Business Officer, Landau Jeffrey B, sold 4,206 shares at a price of $1.42 on Jul 20. Then, on Jul 20, General Counsel ROWLAND LLOYD A sold 5,602 shares at a price of $1.42 per share. This transaction amounted to $7,968.
CTMX stock has a beta of 0.45. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.51 while the price-to-book (PB) in the most recent quarter is 6.40.
CytomX Therapeutics Inc.’s quick ratio for the period ended September 29 was 2.00, with the current ratio over the same period at 2.00. The firm’s gross profit as reported stood at $153.35 million against revenue of $69.57 million.
For the quarterly period ending September 29 this year, CytomX Therapeutics Inc.’s cash and short-term investments amounted to $99.25 million against total debt of $19.02 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 3.09% to -$23.3 million, while revenue of -$24.18 million was -3.78% off the previous quarter. Analysts expected CTMX to announce -$0.31 per share in earnings in its latest quarter, but it posted -$0.35, representing a -12.90% surprise. EBITDA for the quarter stood at more than -$23.33 million. CTMX stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 198.02 million, with total debt at $19.02 million. Shareholders hold equity totaling $66.08 million.
Let’s look briefly at CytomX Therapeutics Inc. (CTMX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 61.96% to suggest the stock is trending Neutral, with historical volatility in this time period at 192.58%.
The stock’s 5-day moving average is $2.63, reflecting a +4.94% or $0.12 change from its current price. CTMX is currently trading +70.65% above its 20-day SMA, +76.33% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +109.92% and SMA200 by-4.51%.
Stochastic %K and %D was 77.80% and 74.95% and the average true range (ATR) pointed at 0.22. The RSI (14) points at 64.51%, while the 14-day stochastic is at 72.22% with the period’s ATR at 0.21. The stock’s 9-day MACD Oscillator is pointing at 0.05 and 0.09 on the 14-day charts.
In the most recent analyst report for CytomX Therapeutics Inc. (NASDAQ: CTMX), BMO Capital Markets downgraded it to a Market perform rating. They previously had an Outperform rating on the stock. Analysts offering their rating for CTMX stock have a consensus rating for the stock as Hold. Currently, 1 brokerage advisors rate CTMX as a “sell,”, while 7 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 0 have offered a “buy” rating.
What is CTMX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $2.00 and a high of $4.00, with their median price target at $2.73. Looking at these predictions, the average price target given by analysts is for CytomX Therapeutics Inc. (CTMX) stock is $2.83.